期刊
CELL DEATH AND DIFFERENTIATION
卷 16, 期 11, 页码 1426-1437出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/cdd.2009.119
关键词
sequestosome1; PKC zeta; PKC lambda; PKC iota; Par-4; cancer
资金
- NCI NIH HHS [R01 CA132847, R01 CA134530] Funding Source: Medline
- NIAID NIH HHS [R01 AI072581] Funding Source: Medline
- NIDDK NIH HHS [R01 DK088107] Funding Source: Medline
The recent identification of a novel protein-protein interaction module, termed PB1, in critical signaling molecules such as p62 (also known as sequestosome1), the atypical PKCs, and Par-6, has unveiled the existence of a new set of signaling complexes, which can be central to several biological processes from development to cancer. In this review, we will discuss the most recent advances on the role that the different components of these complexes have in vivo and that are relevant to human disease. In particular, we will review what we are learning from new data from knockout mice, and the indications from human mutations on the real role of these proteins in the physiology and biology of human diseases. The role that PKC zeta, PKC lambda/iota, and Par-4 have in lung and prostate cancer in vivo and in humans will be extensively covered in this article, as will the multifunctional role of p62 as a novel hub in cell signaling during cancer and inflammation, and the mechanistic details and controversial data published on its potential role in aggregate formation and signaling. All this published information is shedding new light on the proposed pathological implications of these PB1-regulators in disease and shows their important role in cell physiology. Cell Death and Differentiation (2009) 16, 1426-1437; doi:10.1038/cdd.2009.119; published online 28 August 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据